{"url_path":"/sec/imvt/10-k/2026/item-10","section_key":"item-10","section_title":"Item 10 Directors, Executive Officers and Corporate Governance","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000064-index.html","accession_number":"0001764013-26-000064","cik":"0001764013","ticker":"IMVT","issuer_name":"Immunovant, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000064-index.html","primary_entity_key":"0001764013","primary_entity_name":"Immunovant, Inc."},"word_count":194,"has_tables":true,"body_markdown":"Item 10. Directors, Executive Officers and Corporate Governance\n\nThe information required by this item will be contained in our 2026 Proxy Statement under the captions “Information Regarding the Board of Directors and Corporate Governance,” “Meetings of the Board and its Committees” and “Executive Officers” and is incorporated herein by reference.\n\nOur board of directors has adopted a Code of Business Conduct and Ethics (the “Code of Conduct”) that is applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at www.immunovant.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code of Business Conduct and Ethics to the principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions, we will promptly disclose the nature of the amendment or waiver on our website. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of this Annual Report on Form 10-K."}